Biogen Inc Stock Investor Sentiment

BIIB Stock  USD 139.44  0.54  0.39%   
About 57% of Biogen's investor base is looking to short. The analysis of the overall investor sentiment regarding Biogen Inc suggests that many traders are alarmed. The current market sentiment, together with Biogen's historical and current headlines, can help investors time the market. In addition, many technical investors use Biogen Inc stock news signals to limit their universe of possible portfolio assets.

Comfort Level 43

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Biogen's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Biogen Inc.

Biogen Historical Sentiment

Although Biogen's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Biogen, such as negative comments on social media and news outlets, may cause fear in the market and push Biogen's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Biogen.
  

Biogen Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biogen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Biogen Inc Historical Investor Sentiment

Investor biases related to Biogen's public news can be used to forecast risks associated with an investment in Biogen. The trend in average sentiment can be used to explain how an investor holding Biogen can time the market purely based on public headlines and social activities around Biogen Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biogen's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biogen and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biogen news discussions. The higher the estimate score, the more favorable the investor's outlook on Biogen.

Biogen Maximum Pain Price Across June 20th 2025 Option Contracts

Biogen's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Biogen close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Biogen's options.
a minute ago at kalkinemedia.com         
Japan gives priority review status to Alzheimers drug developed by Eisai, Biogen
news
2 days ago at finance.yahoo.com         
Can BIIBs New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Yahoo News
2 days ago at zacks.com         
Why Is Biogen Up 1.1 percent Since Last Earnings Report?
zacks News
2 days ago at finance.yahoo.com         
INOVIOs Covid-19 dMAb maintains in-vivo detection in 100 percent participants
Yahoo News
3 days ago at finance.yahoo.com         
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2...
Yahoo News
few days ago at zacks.com         
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
zacks News
few days ago at finance.yahoo.com         
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
Yahoo News
few days ago at prnewswire.com         
X-ELIO closes six US PPAs with Cisco, Biogen, IDEXX, and Waters Corporation
prnewswire News
few days ago at thestar.com         
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection ...
news
few days ago at businesswire.com         
Biosimilars Market Products, Applications and Regulations Overview 2025 Increasing Cost of Biologic ...
businesswire News
few days ago at zacks.com         
IONSAZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
zacks News
few days ago at finance.yahoo.com         
IONSAZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
Yahoo News
few days ago at gurufocus.com         
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated ...
Gurufocus Stories at Macroaxis
few days ago at globenewswire.com         
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection ...
Macroaxis News: globenewswire.com
few days ago at benzinga.com         
Decoding Biogens Options Activity Whats the Big Picture?
benzinga news
Far too much social signal, news, headlines, and media speculation about Biogen that are available to investors today. That information is available publicly through Biogen media outlets and privately through word of mouth or via Biogen internal channels. However, regardless of the origin, that massive amount of Biogen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biogen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biogen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biogen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biogen alpha.

Biogen Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Mantas Jesus B of 1340 shares of Biogen subject to Rule 16b-3
12/20/2024
2
Biogen Strengthens Pipeline With Stoke Therapeutics Dravet Syndrome Candidate Via Multi-Million Dollar Deal
02/18/2025
3
Apple in NC asked and answered, from RTP campus to latest data center announcement
02/25/2025
4
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
03/05/2025
5
Alzheimers Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
03/06/2025
6
Disposition of 8760 shares by Sherwin Stephen A of Biogen at 150.0162 subject to Rule 16b-3
03/07/2025
7
Biogen Inc Shares Up 3.42 percent on Mar 10
03/10/2025
8
IONSAZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
03/11/2025
9
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
03/12/2025
10
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2 percent - Report by Transparency Market Research, Inc.
03/13/2025

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets